Alvotech Feed

	Est. tid*
2025-11-12	22:50	Kvartalsrapport 2025-Q3
2025-08-14	22:50	Kvartalsrapport 2025-Q2
2025-06-26	-	X-dag ordinarie utdelning ALVO 0.00 ISK
2025-06-25	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-03-26	-	Bokslutskommuniké 2024
2024-11-14	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-03-20	-	Bokslutskommuniké 2023
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2025-07-04 01:02:28 Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

2025-07-02 01:54:39 Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda 1105,00 ISK | -0,90% | 32,0 MISK

2025-07-02 01:54:39 Granting of Stock Options and Vesting of Restricted Share Units 1105,00 ISK | -0,90% | 32,0 MISK

2025-07-01 10:00:00 Alvotech and Advanz Pharma ingår europeiskt leverans- och kommersialiseringsavtal för biosimilarkandidat till Cimzia® (certolizumab pegol) 1115,00 ISK | +0,45% | 53,4 MISK

2025-07-01 10:00:00 Advanz Pharma semur við Alvotech um markaðssetningu í Evrópu á hliðstæðu við líftæknilyfið Cimzia 1115,00 ISK | +0,45% | 53,4 MISK

2025-07-01 10:00:00 Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) 1115,00 ISK | +0,45% | 53,4 MISK

2025-06-26 10:15:00 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Alvotechs långivare sänker räntan på senior säkerställd lånefacilitet 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Lánveitendur Alvotech lækka vexti á langtímaskuldum félagsins 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 22:45:00 Niðurstaða aðalfundar Alvotech árið 2025 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 22:45:00 Main Results of 2025 Annual and Extraordinary General Meeting 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 10:00:00 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-25 10:00:00 Jákvæð niðurstaða úr klínískri rannsókn fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-25 10:00:00 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-23 10:00:00 Lyfjastofnun Evrópu mælir með því að veita markaðsleyfi fyrir AVT06, fyrirhugaða hliðstæðu Alvotech við augnlyfið Eylea 176 MISK

2025-06-23 10:00:00 European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept) 176 MISK

2025-06-11 22:20:10 Öll bréf afhent kaupendum í hlutafjárútboði Alvotech 1235,00 ISK | -0,40% | 134 MISK

2025-06-11 22:20:10 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors 1235,00 ISK | -0,40% | 134 MISK

2025-06-11 22:18:08 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors 1235,00 ISK | -0,40% | 134 MISK

2025-06-06 14:30:00 Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami 1360,00 ISK | +0,74%

2025-06-06 14:30:00 Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans í Miami 1360,00 ISK | +0,74%

2025-06-06 14:30:00 Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami 1360,00 ISK | +0,74%

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 08:55:00 Alvotech og Dr. Reddys ganga til samstarfs um þróun hliðstæðu við krabbameinslyfið Keytruda 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 04:29:32 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 01:55:00 Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 01:55:00 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 17:32:42 Alvotech ráðgerir útboð til stofnanafjárfesta á um 7,5 milljónum sænskra heimildarskírteina og hlutabréfum 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 17:32:42 Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 13:45:00 Alvotech lýkur við kaup á rannsóknaraðstöðu Xbrane og fyrirhugaðri hliðstæðu við Cimzia 1440,00 ISK | 0,00% | 8,76 MISK

2025-06-04 13:45:00 Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® 1440,00 ISK | 0,00% | 8,76 MISK

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech fundar með fjárfestum á árlegri heilbrigðisráðstefnu Jefferies fjárfestingabankans í New York og flytur kynningu 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Advanz Pharma semur við Alvotech um rétt til markaðssetningar þriggja fyrirhugaðra hliðstæða til viðbótar í Evrópu 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-26 20:06:57 Aðalfundur Alvotech boðaður 25. júní 2025 1395,00 ISK | +2,20%

2025-05-26 20:06:57 Alvotech Annual General Meeting to be held June 25, 2025 1395,00 ISK | +2,20%

2025-05-23 18:11:25 Viðskipti stjórnenda og tengdra aðila 1275,00 ISK | -1,16%

2025-05-23 18:11:25 Transactions of Managers and Closely Associated Persons 1275,00 ISK | -1,16%

2025-05-19 09:15:00 Alvotech semur við fjárfestingabankann DNB Carnegie um viðskiptavakt á Nasdaq markaðnum í Stokkhólmi 1330,00 ISK | -1,48%

2025-05-19 09:15:00 Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm 1330,00 ISK | -1,48%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Alvotech

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden